Fairfax-backed Go Digit General Insurance files IPO papers with Sebi
时间:2024-06-26 16:58:51 阅读(143)
Go Digit General Insurance Ltd, backed by Canada-based Fairfax Group, has filed preliminary papers with markets regulator Sebi to garner funds through an initial public offering (IPO). The IPO comprises fresh issuance of equity shares worth Rs 1,250 crore and an offer-for-sale (OFS) of 10,94,45,561 equity shares by a promoter and existing shareholders, according to the draft red herring prospectus (DRHP).
Under the OFS, Go Digit Infoworks Services Pvt Ltd will sell 10,94,34,783 equity shares. Also, the company may consider a pre-IPO placement of equity shares aggregating up to Rs 250 crore. If such placement is completed, the fresh issue size will be reduced.
Also read| Balaji Solutions files draft papers with Sebi to raise funds via IPO
It is one of the first non-life insurers in India to be fully operated on the cloud and has developed application programming interface (API) integrations with several channel partners.As per the draft papers, cricketer Virat Kohli and his wife Anushka Sharma are among the investors of Go Digit General Insurance.
The Bengaluru-based company has a track record of delivering growth with Gross Written Premium (GWP) at Rs 5,268 crore, Rs 3,243 crore and Rs 2,252 crore in financial years 2022, 2021, and 2020, with a compound annual growth rate (CAGR) of 53 per cent from fiscal 2020 to fiscal 2022.
Also read| Syrma SGS Technology IPO enters day 2 with 37% issue subscribed, GMP steady; should you bid?
ICICI Securities, Morgan Stanley India Company, Axis Capital, Edelweiss Financial Services, HDFC Bank, and IIFL Securities are the book running lead managers to the issue. The equity shares of the company will be listed on BSE and NSE
猜你喜欢
- Year Ender 2023 - Indian Railways- Measures taken to improve safety in train operations
- Where is share market headed after Nifty closes below 18690, Bank Nifty under 43450; check support, resistance
- s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
- Worried over future contracts, farmers hold on to soyabean stocks, seek better prices
- BharatGPT- Akash Ambani drops key updates on Reliance Jio-IIT Bombay’s key AI project
- Binance Coin (BNB) price prediction- Is it time to shift towards Retik Finance (RETIK)-
- Watch VIDEO- Tourist drives SUV through river to beat traffic in Himachal’s Lahaul
- What airlines, regulators are doing about Boeing 737 MAX 9 jets – Know key facts
- Vibrant Gujarat Summit- Mukesh Ambani calls Reliance a Gujarati firm, says invested one-third of $150 billion investments in state